BR112012013001A2 - formas polimorfas iii e iv de n-benzoil-estaurosporina - Google Patents
formas polimorfas iii e iv de n-benzoil-estaurosporinaInfo
- Publication number
- BR112012013001A2 BR112012013001A2 BR112012013001A BR112012013001A BR112012013001A2 BR 112012013001 A2 BR112012013001 A2 BR 112012013001A2 BR 112012013001 A BR112012013001 A BR 112012013001A BR 112012013001 A BR112012013001 A BR 112012013001A BR 112012013001 A2 BR112012013001 A2 BR 112012013001A2
- Authority
- BR
- Brazil
- Prior art keywords
- staurosporine
- benzoyl
- polymorph forms
- forms iii
- iii
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
formas polimorfas iii e iv de n-benzoil-estaurosporina. a presente invenção refere-se a uma forma cristalina iii e uma forma cristalina iv da n-benzoil estaurosporina. a n-benzoil estaurosporina também é conhecida como a midostaurina ou pck 412.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09177490A EP2327706A1 (en) | 2009-11-30 | 2009-11-30 | Polymorphous forms III and IV of N-benzoyl-staurosporine |
PCT/EP2010/068359 WO2011064355A1 (en) | 2009-11-30 | 2010-11-29 | Polymorphous forms iii and iv of n-benzoyl staurosporine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012013001A2 true BR112012013001A2 (pt) | 2015-09-08 |
Family
ID=42111903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012013001A BR112012013001A2 (pt) | 2009-11-30 | 2010-11-29 | formas polimorfas iii e iv de n-benzoil-estaurosporina |
Country Status (11)
Country | Link |
---|---|
US (2) | US9150589B2 (pt) |
EP (2) | EP2327706A1 (pt) |
JP (2) | JP2013512230A (pt) |
KR (1) | KR20120101698A (pt) |
CN (2) | CN104211717A (pt) |
AU (1) | AU2010323071B2 (pt) |
BR (1) | BR112012013001A2 (pt) |
CA (1) | CA2780970C (pt) |
MX (2) | MX340946B (pt) |
RU (1) | RU2598378C2 (pt) |
WO (1) | WO2011064355A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007284615B2 (en) * | 2006-08-16 | 2011-10-27 | Novartis Ag | Method for making solid dispersions of highly crystalline therapeutic compounds |
EP3592749A1 (en) | 2017-03-06 | 2020-01-15 | Teva Pharmaceutical Works Ltd. | Solid state forms of midostaurin |
IT201900004729A1 (it) | 2019-03-29 | 2020-09-29 | Procos Spa | Processo per la preparazione di midostaurina ad elevato grado di purezza |
CN111393454A (zh) * | 2020-05-07 | 2020-07-10 | 奥锐特药业(天津)有限公司 | 米哚妥林的新晶型及其制备方法 |
CN112812129A (zh) * | 2020-12-31 | 2021-05-18 | 浙江海正药业股份有限公司 | 米哚妥林的新晶型及其制备方法和用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
JPH05247055A (ja) * | 1992-03-03 | 1993-09-24 | Meiji Seika Kaisha Ltd | スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤 |
CN1582150B (zh) * | 2001-10-30 | 2011-09-07 | 诺瓦提斯公司 | 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物 |
KR101179393B1 (ko) * | 2004-03-23 | 2012-09-07 | 노파르티스 아게 | 제약 조성물 |
GB0406515D0 (en) * | 2004-03-23 | 2004-04-28 | Novartis Ag | Organic compounds |
JO2897B1 (en) | 2004-11-05 | 2015-09-15 | نوفارتيس ايه جي | Organic compounds |
CN101665498A (zh) * | 2004-11-05 | 2010-03-10 | 诺瓦提斯公司 | 有机化合物 |
AU2007284615B2 (en) | 2006-08-16 | 2011-10-27 | Novartis Ag | Method for making solid dispersions of highly crystalline therapeutic compounds |
-
2009
- 2009-11-30 EP EP09177490A patent/EP2327706A1/en not_active Ceased
-
2010
- 2010-11-29 US US13/512,398 patent/US9150589B2/en active Active
- 2010-11-29 JP JP2012540449A patent/JP2013512230A/ja active Pending
- 2010-11-29 BR BR112012013001A patent/BR112012013001A2/pt not_active IP Right Cessation
- 2010-11-29 CN CN201410345641.0A patent/CN104211717A/zh active Pending
- 2010-11-29 WO PCT/EP2010/068359 patent/WO2011064355A1/en active Application Filing
- 2010-11-29 KR KR1020127016980A patent/KR20120101698A/ko not_active Application Discontinuation
- 2010-11-29 MX MX2012006181A patent/MX340946B/es active IP Right Grant
- 2010-11-29 RU RU2012127085/04A patent/RU2598378C2/ru active
- 2010-11-29 CN CN201080054097.4A patent/CN102639538A/zh active Pending
- 2010-11-29 MX MX2015002221A patent/MX351177B/es unknown
- 2010-11-29 EP EP10785056A patent/EP2507246A1/en not_active Withdrawn
- 2010-11-29 AU AU2010323071A patent/AU2010323071B2/en active Active
- 2010-11-29 CA CA2780970A patent/CA2780970C/en active Active
-
2015
- 2015-08-27 US US14/837,792 patent/US9593130B2/en active Active
- 2015-12-11 JP JP2015241787A patent/JP2016104755A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
KR20120101698A (ko) | 2012-09-14 |
US20150368268A1 (en) | 2015-12-24 |
MX351177B (es) | 2017-10-04 |
JP2013512230A (ja) | 2013-04-11 |
US9593130B2 (en) | 2017-03-14 |
CA2780970A1 (en) | 2011-06-03 |
US9150589B2 (en) | 2015-10-06 |
AU2010323071A1 (en) | 2012-06-07 |
RU2598378C2 (ru) | 2016-09-27 |
AU2010323071B2 (en) | 2014-11-13 |
US20120245160A1 (en) | 2012-09-27 |
WO2011064355A1 (en) | 2011-06-03 |
EP2327706A1 (en) | 2011-06-01 |
JP2016104755A (ja) | 2016-06-09 |
CN102639538A (zh) | 2012-08-15 |
CA2780970C (en) | 2018-07-10 |
EP2507246A1 (en) | 2012-10-10 |
MX340946B (es) | 2016-08-01 |
MX2012006181A (es) | 2012-06-19 |
CN104211717A (zh) | 2014-12-17 |
RU2012127085A (ru) | 2014-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20120295A (es) | Triazolopiridinas | |
DK2236598T3 (da) | Mikroorganismer til forbedring af helbredet hos individer med lidelser i forbindelse med fordøjelse af gluten | |
ZA201107806B (en) | Organisms for the production of 1,3-butanediol | |
ZA201102782B (en) | Sporulation-deficient termophilic microorganisms for the production of ethanol | |
BRPI1011952A2 (pt) | "composições de combustível compreendendo derivados de isopreno" | |
BR112012008156A2 (pt) | conjunto de cateter com abertura reselável | |
BR112012004781A2 (pt) | diagnóstico de interferon tipo 1 | |
WO2011050582A8 (en) | Classification of sematosensory evoked potential waveforms | |
CR20120297A (es) | Espironucleósidos uracílicos oxetánicos | |
BRPI1008488A2 (pt) | diagnóstico melhorado de fibrose ou cirrose do fígado | |
EP2331089A4 (en) | USES OF SESQUITERPENE DERIVATIVES | |
IT1393061B1 (it) | Procedimento integrato per la produzione di bio-olio da microrganismi | |
BRPI0907099A2 (pt) | Derivados de isoxazol como moduladores de 11-beta-hidroxiesteróide desidrogenase tipo 1 | |
BR112012005503A2 (pt) | derivados de isoxazolidina | |
BRPI0909422A2 (pt) | conjunto de artigos. | |
BR112012013001A2 (pt) | formas polimorfas iii e iv de n-benzoil-estaurosporina | |
PT2408719E (pt) | Composições para o condicionamento de lamas | |
BRPI0911678A2 (pt) | forma cristalina anidrosa de maleato de orvepitant | |
BR112012002268A2 (pt) | fotoestabailização de retinóides com compostos de alcóxicrileno | |
NI200900154A (es) | Nuevos procedimiento de obtención de la forma cristalina v de la agomelatina | |
BRPI0907156A2 (pt) | Produção de etanol aumentada por células bacterianas | |
CR20140545A (es) | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino [1,2-a]indol-1-ona | |
ZA201104657B (en) | Synthesis of morphine-6-glucuronide or one of the derivatives thereof | |
BR112012002575A2 (pt) | utilização de uma composição. | |
FR2948680B1 (fr) | Nouveaux mutants de la pqq s-gdh |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2542 DE 24-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |